Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov 16:10:592996.
doi: 10.3389/fonc.2020.592996. eCollection 2020.

The History of the Chemo-Free Model in the Treatment of Acute Promyelocytic Leukemia

Hong-Hu Zhu  1
Affiliations
Review

The History of the Chemo-Free Model in the Treatment of Acute Promyelocytic Leukemia

Hong-Hu Zhu. Front Oncol. .

Abstract

Acute promyelocytic leukemia (APL) has become a highly curable disease after four decades of endeavors. Thanks to the efforts of investigators throughout the world, the chemo-free concept has become a reality for both low- and high-risk patients. All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) without chemotherapy has become a first-line treatment for newly diagnosed APL and has been adopted in guidelines or expert recommendations from the NCCN and ELN and in China. Though the regimen has achieved great success, challenges still exist. The rate of early death still has not diminished significantly and is a major obstacle to curing all patients. Leukocytosis is the most important factor for ED, and completely abandoning chemotherapy is dangerous for certain patients in practice. To narrow the gap between guidelines and practice, this review aims to examine the history of the chemo-free model for the treatment of APL in the arsenic-alone era (1974-2002) and the arsenic plus ATRA era (2002-present) and provide practical considerations regarding early death.

Keywords: ATO; ATRA; acute promyelocytic leukemia; chemotherapy; early death.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The history of the chemo-free model for newly diagnosed acute promyelocytic leukemia.
See this image and copyright information in PMC

References

    1. Sun HD, Ma L, Hu XC, Zhang TD, Rong FX, Wang X, et al. The clinical report of 16 long-term survivors of acute promyelocytic leukemia treated with Ai-Ling 1 and traditional Chinese medicine. Inf Tradit Chin Med (1991) 06):39–41.
    1. Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, et al. Seven years’ summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide–an analysis of 242 cases. Zhonghua Xue Ye Xue Za Zhi (2000) 21(2):67–70. - PubMed
    1. Lu D, Qiu J, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood (2002) 99(9):3136–43. 10.1182/blood.V99.9.3136 - DOI - PubMed
    1. Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood (2006) 107:2627–32. 10.1182/blood-2005-08-3532 - DOI - PubMed
    1. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol (2006) 17:131–4. 10.1093/annonc/mdj019 - DOI - PubMed